AALL1821 - A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC # 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged Greater than or equal to 1 to < 31 Years Old with First Relapse

Is this Study for You?

Let's Get Started!


Child to Adult

Type of Study



Childrens Hospital Colorado

Principal Investigator
Photograph of Kelly Faulk,  MD

Kelly Faulk, MD

Study ID

Protocol Number: 21-3049

More information available at ClinicalTrials.gov: NCT04546399

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers